These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
146 related items for PubMed ID: 2994153
1. The GABA hypothesis of depression and antidepressant drug action. Bartholini G, Lloyd KG, Scatton B, Zivkovic B, Morselli PL. Psychopharmacol Bull; 1985; 21(3):385-8. PubMed ID: 2994153 [No Abstract] [Full Text] [Related]
2. Mechanisms of action of antidepressant drugs. Hamon M. Adv Biosci; 1985; 21():117-28. PubMed ID: 385392 [No Abstract] [Full Text] [Related]
3. [Biochemistry of manic-depressive disorders (III)--Action mechanisms of therapeutic drugs]. Takahashi R, Semba J. Tanpakushitsu Kakusan Koso; 1988 Aug; 33(10):1702-7. PubMed ID: 3074349 [No Abstract] [Full Text] [Related]
4. Upregulation of gamma-aminobutyric acid (GABA) B binding sites in rat frontal cortex: a common action of repeated administration of different classes of antidepressants and electroshock. Lloyd KG, Thuret F, Pilc A. J Pharmacol Exp Ther; 1985 Oct; 235(1):191-9. PubMed ID: 2995646 [Abstract] [Full Text] [Related]
5. [Current views of the mechanism of action of antidepressants]. Zieba A, Pawłowski L. Psychiatr Pol; 1993 Oct; 27(3):317-24. PubMed ID: 8356178 [Abstract] [Full Text] [Related]
6. Monoamine receptor sensitivity and the mechanism of action of antidepressant treatment. Psychopharmacol Bull; 1982 Jul; 18(3):130-55. PubMed ID: 6292986 [No Abstract] [Full Text] [Related]
8. [On the mechanism of therapeutic actions of psychotropic drugs (author's transl)]. Mroji T. No To Shinkei; 1979 Nov; 31(11):1075-97. PubMed ID: 43160 [No Abstract] [Full Text] [Related]
12. GABAergic contributions to the pathophysiology of depression and the mechanism of antidepressant action. Sanacora G, Saricicek A. CNS Neurol Disord Drug Targets; 2007 Apr; 6(2):127-40. PubMed ID: 17430150 [Abstract] [Full Text] [Related]
13. [Neuropharmacological approach to major depression]. Nakazawa K. Yakubutsu Seishin Kodo; 1991 Apr; 11(2):171-6. PubMed ID: 1656650 [No Abstract] [Full Text] [Related]
14. [Monoamines and endogenous depression. Biochemical and pharmacological aspects]. Scuvée-Moreau J, Dresse A. Rev Med Liege; 1982 Jan 01; 37(1):1-7. PubMed ID: 7054862 [No Abstract] [Full Text] [Related]
15. [Experimental and clinical characteristics of the Soviet antidepressant inkasan]. Mashkovskiĭ MD, Andreeva NI. Zh Nevropatol Psikhiatr Im S S Korsakova; 1984 Jan 01; 84(3):410-3. PubMed ID: 6720183 [Abstract] [Full Text] [Related]
16. Pharmacologic properties of serotonergic agents and antidepressant drugs. Fuller RW. J Clin Psychiatry; 1987 Mar 01; 48 Suppl():5-11. PubMed ID: 3493240 [Abstract] [Full Text] [Related]
17. Use of monoamine oxidase inhibitors in chronic neurodegeneration. Riederer P, Müller T. Expert Opin Drug Metab Toxicol; 2017 Feb 01; 13(2):233-240. PubMed ID: 27998194 [Abstract] [Full Text] [Related]
18. New antidepressant drugs: beyond monoaminergic mechanisms. Alamo C, López-Muñoz F. Curr Pharm Des; 2009 Feb 01; 15(14):1559-62. PubMed ID: 19442173 [No Abstract] [Full Text] [Related]
19. Fengabine, a novel antidepressant GABAergic agent. I. Activity in models for antidepressant drugs and psychopharmacological profile. Lloyd KG, Zivkovic B, Sanger D, Depoortere H, Bartholini G. J Pharmacol Exp Ther; 1987 Apr 01; 241(1):245-50. PubMed ID: 3033203 [Abstract] [Full Text] [Related]
20. Half a century of antidepressant drugs: on the clinical introduction of monoamine oxidase inhibitors, tricyclics, and tetracyclics. Part I: monoamine oxidase inhibitors. López-Muñoz F, Alamo C, Juckel G, Assion HJ. J Clin Psychopharmacol; 2007 Dec 01; 27(6):555-9. PubMed ID: 18004120 [No Abstract] [Full Text] [Related] Page: [Next] [New Search]